Statin With Palliative Therapy for HCC

Taipei Medical University

Status

Terminated

Conditions

HCC

Treatments

Drug: Statin

Study type

Interventional

Funder types

Other

Identifiers

NCT02785874

N201603038

Details and patient eligibility

About

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer,however, the investigators also discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

Full description

Most liver cancer patients did not accept the cure as the main objective of the treatment after diagnosis because they choose alternative therapies palliative based, such as hepatic arterial chemoembolization, chemotherapy and radiation therapy.

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer, yet the clinical effect for Statin is still unknown.

In a previous study of 20,220 liver cancer patients in health care database, the investigators discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

This study is a continuation of previous health insurance database studies for clinical trials to verify whether Statin could prolong disease-free survival role for palliative treatment of liver cancer.

Enrollment

4 patients

Sex

All

Ages

20 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

>20 years old.
BCLC stage B , stage C and stage D

Exclusion criteria

Cancer diagnosis before HCC was conﬁrmed and incurable.
<20 years old, > 90years old.
Patients who are judged to be ineligible for study entry by the investigator or subinvestigator